JNJ•benzinga•
Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Mode
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga